In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phytopharm PLC

Division of Ixico Ltd.
www.phytopharm.com

Latest From Phytopharm PLC

Stockwatch: Lax Approval Requirements Yield Blockbusters That Don’t Work

With the backdrop of Biogen’s BLA filing, and the FDA’s expected response for aducanumab in Alzheimer’s disease in 2020, the link between efficacy and approval seems to have broken. Conditional FDA approvals can’t help when the conditions are ignored.

Stockwatch Clinical Trials

Phytopharm becomes vehicle for IXICO listing

The struggling UK pharmaceutical company Phytopharm is to be subsumed into dementia diagnostics firm IXICO in a reverse takeover worth around £5.6m ($9m). Phytopharm's shares have been in the doldrums since it reported in February that its Cogane drug candidate had failed in a Phase II trial in early-stage Parkinson's disease (scripintelligence.com, 18 February 2013). It will now become a vehicle for the privately held UK firm IXICO to gain a public listing.

Neurology

STOCKWATCH: The strategic review – a prelude to value destruction

The news that a company is conducting a strategic review has grandiose implications of high-flying investment bankers, consultants and board members scouring the world and the management literature for examples of how successful companies have moved from strength to strength, and then how those lesions can be applied to the company in question.

Cancer Orthopedics

Phytopharm dives on 'comprehensive' Cogane failure in Parkinson's

Phytopharm's Cogane has comprehensively failed the Phase II CONFIDENT-PD trial for the treatment of early stage Parkinson's disease patients.

Neurology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
    • Nutraceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Ixico Ltd.
  • Senior Management
  • Sandy Morrison, Acting CEO
    Piers Morgan, CFO
  • Contact Info
  • Phytopharm PLC
    Phone: (44) 1480 437697
    Corpus Christi House
    9 West St.
    Godmanchester, PE29 2HY
    UK
UsernamePublicRestriction

Register